Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rash

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    295 result(s) found for: Rash. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-000877-29 Sponsor Protocol Number: GEOS-01-2011 Start Date*: 2011-12-02
    Sponsor Name:Grupo de Estudos Oncológicos
    Full Title: Phase III clinical trial for evaluation of prophylactic treatment with minocycline versus reactive treatment of dermatological toxicity secondary to cetuximab in patients with metastatic colorectal...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10037844 Rash PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000390-30 Sponsor Protocol Number: ML20128 Start Date*: 2006-05-18
    Sponsor Name:Helsinki University Central Hospital, Skin and Allergy Hospital
    Full Title: A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rash
    Medical condition: The study population are patients with non-small cell lung carcinoma eligible for treatment with erlotinib (TarcevaTM). A significant number of these patients develop acne-like rash as a side effec...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002895-32 Sponsor Protocol Number: ML21308 Start Date*: 2007-08-29
    Sponsor Name:Roche AB
    Full Title: A phase II trial assessing Metronidazol Actavis 1% topical cream in the prevention and treatment of Erlotinib associated rash
    Medical condition: Erlotinib associated rash
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000608-13 Sponsor Protocol Number: MK-4117-201 Start Date*: 2017-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III multicentre, parallel-group, randomized, placebo-controlled, double-blind clinical trial to study the efficacy and safety of MK-4117 in Japanese subjects with chronic urticaria.
    Medical condition: Chronic urticaria (a skin condition caused by an allergy)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003567-22 Sponsor Protocol Number: Zincox12 Start Date*: 2012-12-05
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: Efficacy of topical application of zinc oxide ointment compared with zinc oxide paste and tocoferol, for treating diaper dermatitis in infant: a randomized, controlled, triple blind study
    Medical condition: Diaper dermatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10012444 Dermatitis diaper PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002818-13 Sponsor Protocol Number: DEALSZ-2021-001 Start Date*: 2023-05-12
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit...
    Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003494-22 Sponsor Protocol Number: ANB019-207 Start Date*: 2021-02-24
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects with Cancer Receiving EGFRi or MEKi Therapy
    Medical condition: Acneiform Rash
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037847 Rash acneiform LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) BG (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000169-17 Sponsor Protocol Number: D3259C00001 Start Date*: 2020-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b Multinational, Randomized, Double-blind, Parallel Group, 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Chronic Spontaneo...
    Medical condition: chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10046735 Urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003136-23 Sponsor Protocol Number: CRO1990 Start Date*: 2012-11-27
    Sponsor Name:Imperial College London
    Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10042033 Stevens-Johnson syndrome PT
    14.1 10029205 - Nervous system disorders 10019211 Headache PT
    15.0 100000004856 10028821 Nausea with vomiting LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10040913 Skin rash LLT
    14.1 10029205 - Nervous system disorders 10024264 Lethargy PT
    14.1 10029205 - Nervous system disorders 10013649 Drowsiness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022044-20 Sponsor Protocol Number: CETUDOXI2010 Start Date*: 2010-12-20
    Sponsor Name:María de los Ángeles Álvarez López
    Full Title: Ensayo aleatorizado, doble ciego y controlado con placebo de doxiciclina en la prevención de la erupción acneiforme por cetuximab.
    Medical condition: Erupción acneiforme secundaria al tratamiento con cetuximab.
    Disease: Version SOC Term Classification Code Term Level
    13 10037847 Erupción acneiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003011-26 Sponsor Protocol Number: BILA-4021/PED Start Date*: 2021-10-26
    Sponsor Name:FAES FARMA S.A.
    Full Title: A multicentre, open-label clinical trial to assess plasma levels and safety of bilastine in children from 2 to 5 years of age with seasonal and/or perennial allergic rhinoconjunctivitis or urticaria
    Medical condition: Allergic rhinoconjunctivitis. Urticaria.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10046735 Urticaria PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004739-22 Sponsor Protocol Number: DER-201805 Start Date*: 2021-03-16
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: Efficacy of ruxolitinib cream in Prurigo nodularis patients: A randomized, placebo-controlled pilot study (PRUX)
    Medical condition: Patients with symptomatic Prurigo nodularis with active skin manifestations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037084 Prurigo nodularis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001518-34 Sponsor Protocol Number: ML20296 Start Date*: 2006-07-17
    Sponsor Name:Roche Farma, S.A.
    Full Title: Estudio fase II abierto, no aleatorizado, de erlotinib en combinación con gemcitabina en pacientes con adenocarcinoma de páncreas avanzado irresecable o metastásico: relación entre rash cutáneo y ...
    Medical condition: Adenocarcinoma de páncreas avanzado irresecable o metastásico [Advanced unresectable or metastatic adenocarcinoma of the pancreas].
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001505-17 Sponsor Protocol Number: BILA-3716/PRU Start Date*: 2016-07-29
    Sponsor Name:FAES FARMA, S.A.
    Full Title: An exploratory study to evaluate the efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases.
    Medical condition: Chronic spontaneous urticaria and the following skin disorders: 1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermat...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10012435 Dermatitis and eczema HLT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-003248-36 Sponsor Protocol Number: 61383082 Start Date*: 2011-09-30
    Sponsor Name:Central Military Hospital
    Full Title: The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.
    Medical condition: The aim of the study to estimate frequence of epigenetics changes in pancreatic cancer and to assess the signidicance of apllication of the intravenous contrast agent during endosonography to bette...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016335 Feeling hot and cold LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037872 Rash NOS LLT
    14.0 10037175 - Psychiatric disorders 10032168 Other insomnia LLT
    14.0 10007541 - Cardiac disorders 10008481 Chest pain - cardiac LLT
    14.0 10017947 - Gastrointestinal disorders 10064907 Functional abdominal pain LLT
    14.0 10029205 - Nervous system disorders 10048324 Dizziness aggravated LLT
    14.0 10029205 - Nervous system disorders 10033777 Paraesthesia distal LLT
    14.0 10022891 - Investigations 10050786 Fasting blood glucose increased LLT
    14.0 10018065 - General disorders and administration site conditions 10022096 Injection site reaction NOS LLT
    14.0 10021881 - Infections and infestations 10034838 Pharyngitis NOS LLT
    14.0 10018065 - General disorders and administration site conditions 10016259 Fatigueability LLT
    14.0 10021428 - Immune system disorders 10020762 Hypersensitivity type I LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048412 Back pain aggravated LLT
    14.0 10021428 - Immune system disorders 10020756 Hypersensitivity reaction LLT
    14.0 10017947 - Gastrointestinal disorders 10028822 Nauseated LLT
    14.0 10047065 - Vascular disorders 10048347 Flushing aggravated LLT
    14.0 10029205 - Nervous system disorders 10024857 Loss of consiousness LLT
    14.0 10029205 - Nervous system disorders 10019218 Headache NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037096 Pruritus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003672-36 Sponsor Protocol Number: 115231,MMR159 Start Date*: 2014-10-09
    Sponsor Name:GlaxoSmithKline Biologicals S.A.
    Full Title: A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine wh...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy subjects, 7 years of age and older).
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10069547 Mumps immunization LLT
    17.1 100000004862 10039276 Rubella with unspecified complications LLT
    17.1 100000004865 10069545 Measles immunization LLT
    17.1 100000004862 10039274 Rubella with other specified complication LLT
    17.1 100000004865 10069564 Rubella immunization LLT
    17.1 100000004862 10028274 Mumps with other specified complication LLT
    17.1 100000004862 10027021 Measles without mention of complication LLT
    17.1 100000004862 10027020 Measles with unspecified complication LLT
    17.1 100000004858 10027022 Measles-like rash LLT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002793-30 Sponsor Protocol Number: CLISO2 Start Date*: 2013-05-13
    Sponsor Name:A.O. SAN GERARDO
    Full Title: PHASE II RANDOMIZED STUDY FOR THE PREVENTION OF CUTANEOUS RASH INDUCED BY ERLOTINIB
    Medical condition: metastatic inoperable tumour for NSCLC
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004047-86 Sponsor Protocol Number: AIS-A03 Start Date*: Information not available in EudraCT
    Sponsor Name:Alpine Immune Sciences, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPN-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10042946 Systemic lupus erythematosus rash PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042948 Systemic lupus erythematosus syndrome aggravated LLT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042947 Systemic lupus erythematosus synd LLT
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    20.1 10022891 - Investigations 10067657 Systemic lupus erythematosus disease activity index increased PT
    20.0 10022891 - Investigations 10067658 Systemic lupus erythematosus disease activity index decreased PT
    20.1 10022891 - Investigations 10067659 Systemic lupus erythematosus disease activity index abnormal PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10080670 Systemic lupus erythematosus reactivation LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10073694 Lupus pleurisy PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10040968 SLE arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) ES (Prematurely Ended) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006161-18 Sponsor Protocol Number: 115650 Start Date*: 2014-09-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & Co., Inc....
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases in healthy children, 12 to 15 months of age)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10069547 Mumps immunization LLT
    18.0 100000004862 10039276 Rubella with unspecified complications LLT
    18.0 100000004862 10039274 Rubella with other specified complication LLT
    18.0 100000004865 10069545 Measles immunization LLT
    18.0 100000004865 10069564 Rubella immunization LLT
    18.0 100000004862 10028276 Mumps with unspecified complication LLT
    18.0 100000004862 10027015 Measles like illness LLT
    18.0 100000004862 10028275 Mumps with other specified complications LLT
    18.0 100000004862 10027021 Measles without mention of complication LLT
    18.0 100000004862 10027020 Measles with unspecified complication LLT
    18.0 100000004858 10027022 Measles-like rash LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-004638-32 Sponsor Protocol Number: 115158 Start Date*: 2015-06-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine wh...
    Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy subjects, 4 to 6 years of age).
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10028257 Mumps PT
    18.0 10022891 - Investigations 10059638 Mumps antibody test PT
    18.0 10021881 - Infections and infestations 10027015 Measles like illness LLT
    18.0 10021881 - Infections and infestations 10039270 Rubella viral infections HLT
    18.0 10021881 - Infections and infestations 10027011 Measles PT
    18.0 100000004858 10027022 Measles-like rash LLT
    18.0 10022891 - Investigations 10039261 Rubella immunity (confirmed) LLT
    18.0 10021881 - Infections and infestations 10028262 Mumps like illness LLT
    18.0 10021881 - Infections and infestations 10039252 Rubella PT
    18.0 10022891 - Investigations 10060066 Measles antibody PT
    18.0 10022891 - Investigations 10039255 Rubella antibodies not present LLT
    18.0 10021881 - Infections and infestations 10028268 Mumps viral infections HLT
    18.0 10022891 - Investigations 10039259 Rubella antibody test PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 01:11:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA